

CanREValue

Value-based decisions from Real World Evidence

Winter 2023 Newsletter

Issue 16 | Winter 2023



Happy Holidays!

We would like to thank you for your continued support and contributions to the CanREValue Collaboration!

We wish you and your family a joyous holiday season and a happy and healthy new year!



We have put together a brief newsletter highlighting WG deliverables, publications, and presentations completed over the last year and upcoming stakeholder consultations in 2024.

WORKING GROUP UPDATES AND NEXT STEPS:

Study Objectives

Objective 1: (ongoing)

- ❖ Develop comprehensive understanding of the current state of RWE nationally & internationally
- ❖ Keep current on emerging/new information related to RWE in Canada and beyond

Objective 2: (established & ongoing)

- ❖ Establish formal national working groups dedicated to policy and methodological application of RWE, and collaboratively & iteratively develop a working framework

Objective 3: (ongoing)

- ❖ Validate the developed framework through the completion of a multi-province RWE project

Objective 4: (ongoing)

- ❖ Employ knowledge translation strategies to establish and integrate the final RWE framework

Planning and Drug Selection WG

- Drafted the Policy WG Final Report
- Completed the MCDA validation exercise
- Submitted manuscript describing the MCDA validation exercise

Data WG

- Since Fall 2022, WG has held 4 interprovincial meetings to discuss the RWE demonstration project
- Provinces participating in the RWE demonstration project completed effectiveness analyses. Safety and cost-effectiveness analyses on track to wrap up.
- Drafted the Data WG Final Report

Methods WG

- Updated the Methods WG Report

Reassessment & Uptake WG

- Drafted the Policy WG Final Report

Engagement WG

- Broader stakeholder consultation on the Policy WG Final Report and Data WG Final Report early 2024... more to come in the new year!

NEXT STEPS: The Policy WG final report and Data WG final WG report will be posted online for broader stakeholder review and feedback in early 2024.

RECENT PUBLICATIONS/PRESENTATIONS:

Parmar A, Dai WF, Dionne F, et al. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration. *Curr Oncol*. 2023;30(4):3776-3786. Published 2023 Mar 28. doi:10.3390/curroncol30040286

Takhar P, Dionne F, CanREValue Core Team, and Planning & Drug Selection Working Group. Development of a Multi-Criteria Decision Analysis (MCDA) rating tool to prioritize real-world evidence questions arising from cancer-drug funding decisions. 2023 CADTH Symposium (Oral Presentation), May 16 – 18, 2023.

Geirnaert G, CanREValue Core Team, and MCDA Committee Members. Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) Collaboration: Application of Multi-Criteria Decision Analysis (MCDA) to prioritize re-evaluations of cancer drug funding decisions. 2023 CADTH Symposium (Poster Presentation), May 16 – 18, 2023.

Peacock S (Moderator), Denburg A, Beca J, Dionne F and Ezeife D. The role of Multi-Criteria Decision Analysis (MCDA) within the Canadian Health Technology Assessment landscape. 2023 CADTH Symposium (Panel), May 16 – 18, 2023.

Geirnaert G, CanREValue Team, and MCDA Committee Members. Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) Collaboration: Application of Multi-Criteria Decision Analysis (MCDA) to prioritize re-evaluations of cancer drug funding decisions. ARCC Conference 2023 (Poster Presentation), September 14 – 15, 2023.

Gavura S, Parmar A, Dai WF, Geirnaert, M, Beca J, Denburg A, Takhar P, Mercer R, Tadrous M, Muñoz C, Raphael MJ, and Chan KKW. Development of a Multi-Criteria Decision Analysis (MCDA) Rating Tool to prioritize RWE questions arising from cancer drug funding decision. Ontario Health Research Week 2022 (On-demand presentation), November 29, 2022.

Takhar P, Parmar A, Denburg A, Gavura S, Geirnaert M, Beca J, Mercer R, Muñoz C, Tadrour M, Dai WF, Raphael MJ, and Chan KWW. Application of Multi-Criteria Decision Analysis (MCDA) to prioritize re-evaluations of cancer drug funding decisions. Ontario Health Research Week 2022 (On-demand presentation), November 29, 2022.

Muñoz C. The CanREValue Collaboration: Experience with generating real-world evidence using real-world data from across Canada. NAACCR Talks 2022 (Oral Presentation) , November 2022.